![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Objective: To evaluate the impact of osteoporosis-related fractures on health-related quality of life (HRQoL).
Methods: Data were obtained from the 2016 Adelphi US Osteoporosis Disease Specific Programme™, a cross-sectional survey of physicians and their male and female patients with osteoporosis. Patient-reported outcomes (PRO) measures included the European Quality of Life 5 Domains (EQ-5D), European Quality of Life Visual Analog Scale (EQ-VAS), and Osteoporosis Assessment Questionnaire short-version (OPAQ-SV; physical, emotional, and symptom domains). Associations between PRO scores and the number and site of fractures were evaluated using ANOVA. Multivariate analyses were conducted using linear regression.
Results: Physicians provided records for 1848 patients with osteoporosis. Of these, 981 (53.1%) completed the patient survey, data for the number of fractures were available for 935/981 (95.3%), and 185/935 (19.8%) had a history of fracture. Experiencing fractures significantly influenced scores on all PRO measures (p < .0001). Hip and spine fractures were associated with the greatest reduction in most PRO scores. The number of fractures, age, body mass index, and Charlson Comorbidity Index (CCI) were significantly associated with PRO measures (p < .05) in multivariate analyses. In patients with a fracture, fracture site, CCI, gender (EQ-5D and EQ-VAS), and age (OPAQ-SV physical only) were significantly associated with PRO measures.
Conclusions: In patients with osteoporosis, fractures are associated with lower HRQoL and lower overall health status. Fracture history, fracture site, age, and comorbidity burden significantly influence HRQoL in individuals with osteoporosis. These data suggest the need for interventions to reduce the risk of fractures in patients with osteoporosis.
Transparency
Declaration of funding
Funding for this study was provided by Radius Health, Inc.
Declaration of financial/other relationships
DTG is a consultant for Amgen, Eli Lilly, and Radius Health, Inc. SAW, RJW, YW, and CW are employees of, and own company stock in, Radius Health, Inc. JC and CM are employees of Adelphi Real World, Bollington, UK, and are paid consultants of Radius Health, Inc. SS is a consultant for Amgen, Eli Lilly, and Radius Health, Inc.
Author contributions
SAW and JC contributed to the conception or design of the study. JC contributed to the acquisition of the data. All authors had access to the data and contributed to the data analysis or interpretation. All authors provided a critical review and final approval of the manuscript for publication.
Acknowledgements
All listed authors meet the criteria for authorship set forth by the International Committee for Medical Journal Editors. Medical editorial support (Sarah Hummasti, PhD, and Meher M. Dustoor, PhD) and graphic services were provided by AOIC, LLC, and were funded by Radius Health, Inc.
Data availability statement
The data supporting the findings of this study are commercially available from the 2016 Adelphi US Osteoporosis Disease Specific Programme™. The analysis was conducted using Stata 15.1. Analysis of variance was conducted using command “oneway.” Regression analyses were conducted using command “regress,” with option “VCE cluster” to account for physician clustering. The Protocol Synopsis is available on request by contacting [email protected].